Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 792-801

  Farrugia, David C ^a,b,c   Ford, Hugo E R ^a,b,c   Cunningham, David ^a,b,c   Danenberg, Kathleen D ^a,b,c   Danenberg, Peter V ^a,b,c   Brabender, Jan ^a,b,c   McVicar, A David ^a,b,c   Aherne, G Wynne ^a,b,c   Hardcastle, Anthea ^a,b,c   McCarthy, Keith ^a,b,c   Jackman, Ann L ^a,b,c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CAMPTOTHECIN DERIVATIVE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLYLPOLYGLUTAMATE SYNTHASE; IRINOTECAN; MESSENGER RNA; METHOTREXATE; OXALIPLATIN; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TUMOR BIOPSY;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA PRIMERS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PREDICTIVE VALUE OF TESTS; PROTEIN BIOSYNTHESIS; QUINAZOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIOPHENES; THYMIDYLATE SYNTHASE; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 0037317004     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Advanced Colorectal Cancer Metanalysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
2. Danenberg, P. V. Thymidylate synthetase-a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 473: 73-92, 1977.
3. Pinedo, H. M., and Peters, G. J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
4. Aschele, C., Sobrero, A., Faderan, M. A., and Bertino, J. M. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res., 52: 1855-1864, 1992.
5. Sobrero, A. F., Aschele, C., and Bertino, J. R. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol., 15: 368-381, 1997.
6. Lokich, J. L., Ahlgren, J. D., Gullo, J. L., Phillips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425-432, 1989.
7. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trails testing the biochemical modulation of fluorouracil by methotrexate. J. Clin. Oncol., 12: 960-969, 1994.
8. Saltz, L. B., Cox, J. V., Blanke, C., Rosen. L. S., Fehrenbacker, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
9. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., and Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355: 1041-7, 2000.
10. Levi, F., Zidani, R., and Misset, J. L., for the International Organisation for Cancer Chronotherapy. Randomised multicentre trial of oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet, 350: 681-686, 1997.
11. Sargent, D. J., Niedwiecki, D., O'Connell, M. J., and Schilsky, R. L. Recommendation for caution with irinotecan fluorouracil and leucovorin for colorectal cancer. N. Eng. J. Med., 345: 690-692, 2001.
12. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
13. R (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol., 7: 961-965, 1996.
14. Cocconi, G., Cunningham, D., van Cutsem, E., Fransois, E., Gustavsson, B., van Hazel, G., Kerr, D., Possinger, K., and Heitschold, S. M. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J. Clin. Oncol. Sep., 16: 2943-2952, 1998.
15. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br. J. Cancer, 77(Suppl. 2): 15-21, 1998.
16. Maughan, T. S., James, R. D., Kerr, D., McArdle, C., Ledermann, J. A., Seymour, M., Johnston, C., and Stephens, R. J. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 18: 262a, 1999.
17. Ford, H. E. R., Cunningham, D., Ross, P., Rao, S., Aherne, G. W., Benepal, T. S., Price, T., Massey, A., Vernillet, L., and Gruia, G. Phase I trial of Irinotecan and Raltitrexed in advanced gastrointestinal tract adenocarcinoma. Br. J. Cancer, 83: 146-152, 2000.
18. Fizazi, K., Ducreux, M., Ruffie, P., Bonnay, M., Daniel, C., Soria, J. C., Hill, C., Fandi, A., Poterre, M., Smith, M., and Armand, J. P. Phase I dose finding and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J. Clin. Oncol., 18: 2293-2300, 2000.
19. Douillard, J. Y., Michel, P., Gamelin, E., Conroy, T., Francois, E., Raoul, J. L., Becouarn, Y., Bertheault-Cvitcovic, F., Nasca, S., Ychou, M., Fandi, A., and Seitz, J. F. Raltitrexed ('Tomudex') plus oxaliplatin: an active combination for first line chemotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 19: 250a, 2000.
20. Farrugia, D., Ford, H. E. R., Tischkowitz, M., Joel, S., Kellaway, J., Mitchell, F., Wilson, P., Noyce, C., Jackman, A., Aherne, G. W., and Slevin, M. L. Final results of a phase 1 study of Raltitrexed (Tomudex™) given every 14 days (Q14): a schedule for combination studies. Proc. Am. Soc. Clin. Oncol., 19: 194a, 2000.
21. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, M., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
22. Pestalozzi, B. C., Peterson. H. F., Gelber, R. D., Goldhirsch, A., Gusterson, B., Trihia, H., Lindtner, J., Cortes-Funes, H., Simmoncini, E., Byrne, M. J., Golouh, R., Rudenstam. C. M., Castiglione-Gertsch, M., Allegra, C. J., and Johnston, P. G. Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol., 15: 1923-1931, 1997.
23. Findlay, M. P., Cunningham, D., Morgan, C., Clinton, S., Hardcastle. A., and Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer, 75: 903-909, 1997.
24. Parise, O., Janot, F., Luboinski, B., Massaad, L., Albin, N., Toussaint, C., Verjus, M. A., Bonnay, M., Gouyette, A., and Chabot, C. G. Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head Neck, 16: 158-164, 1994.
25. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
26. Lenz, H. J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groschen, S., Cohen, H., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman. L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J. Clin. Oncol., 14: 176-182, 1996.
27. Leichman, C. G., Lenz, H-J., Leichman, L., Danenberg, K., Baranda, J., Groschen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
28. Metzger, R., Danenberg, K., Leichman. C. G., Salonga, D., Schwartz, E. L., Wadler, S., Lenz, H. J., Groshnen, S., Leichman, L., and Danenberg, P. V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res., 4: 2371-2376, 1998.
29. Salonga, D., Danenberg, K. D., Johnson, M., Metzger, R., Groshen, S., Tsao-Wei, D. D., Lenz, H. J., Leichman, C. G., Leichman, L., Diasio, R. B., and Danenberg, P. V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 6: 1322-1327, 2000.
30. Evrard, A., Cuq, P., Robert, B., Vian, L., Pelegrin, A., and Cano, J. P. Enhancement of 5-fluorouracil cytotoxicity by human thymidinephosphorylase expression in cancer cells: in vitro and in vivo study. Int. J. Cancer. 80: 465-470, 1999.
31. Miller. A., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
32. Zalcberg, J. R., Cunningham, D., Van Cutsem, E., Francois, E., Schornagel, J., Adenis, A., Green, M., Iveson. A., Azab, M., and Seymour, I. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol., 14: 716-721, 1996.
33. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
34. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
35. Gibson, U. E., Heid, C. A., and Williams, P. M. A novel method for real time quantitative RT-PCR. Genome Res., 6: 995-1001, 1996.
36. Aherne, G. W., Ward, E., Lawrence, N., Dobinson. D., Clarke, S. J. Musgrove, H., Sutcliffe, F., Stephens, T., and Jackman, A. L. Comparison of plasma and tissue levels of ZD1694 (Tomudex), a highly polyglutamatable quinazoline thymidylate synthase inhibitor, in preclinical models. Br. J. Cancer. 77: 221-226, 1998.
37. Ardalan, B., and Dang, Z. Thymidylate synthase gene expression in normal and malignant colorectal tissues: relation to in vivo response and survival. Proc. Am. Assoc. Cancer Res., 37: 201, 1996.
38. Davis, R. A., Sticca, R. P., Dunlap, R. B., Berger, F. G., and Berger, S. H. Thymidylate synthase variation in human colonic tissues. Proc. Am. Assoc. Cancer Res., 37: 175, 1996.
39. Shiga, H., Heath, E., Rasmussen, A., Trock, B., Johnston, P. G., Forastiere, A. A., Langmacher, M., Baylor, A., Lee, M., and Cullen, K. J. Prognostic value of p53. Glutathione S-transferase and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res., 5: 4097-4104, 1999.
40. Bathe, O., Francesci, D., Livingstone, A., Moffatt. F. L., Tian, E., and Ardalan, B. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J. Sci. Am., 5: 34-40, 1999.
41. Paradiso, A., Simone, G., Petroni, S., Leone, B., Vallejo, C., Lacava, J., Romero, A., Machiavelli, M., De Lena. M., Allegra, C. J., and Johnston, P. G. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br. J. Cancer, 82: 560-567, 2000.
42. Cascinu, S., Aschele, C., Barni, S., Debernadis, D., Baldo, C., Tunesi, G., Catalano, V., Staccioli, M. P., Brenna, A., Muretto, P., and Catalano, G. Thymidylate synthase protein expression in advanced colon cancer: correlation with site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin. Cancer Res., 5: 1996-1999, 1999.
43. Lizard-Nacol, S., Genne, P., Coudert, B., Riedinger, J. M., Arnal, M., Sancy, C., Brunet-Lecomte, P., and Fargeot, P. MDR1. Thymidylate synthase gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of patients. Anticancer Res., 19: 3575-3582, 1999.
44. Sanguedolce, R., Vultaggio, G., Sanguedolce, F., Modica, G., Li Volsi, F., Diana, G., Guereio, G., Bellanca, L., and Rausa, L. The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res., 18: 1515-1520, 1998.
45. Suzuki, M., Tsukagoshi, S., Saga, Y., Ohwada, M., and Sato, I. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology. 57: 50-54, 1999.
46. Vokes, E., Johnston, P., Recant. W., Mick, R., Behan, K., Dolan, M., Ratain, M., Beckmann. E., Weichselbaum, R., Kozloff, M., and Allegra, C. Thymidylate synthase (TS) expression in advanced head and neck cancer (HNC). Proc. Am. Soc. Clin. Oncol., 15: 313, 1996.
47. Johnston, P., Gilmore, P., and Church, S. The development and optimisation of a quantitative RT-PCR technique from formalin-fixed and paraffin-embedded tissues, using the thymidylate synthase gene as target. Ann. Oncol., 9(Suppl. 4): 120, 1998.
48. Chu, E., Koeller, D. M., Casey, J. L., Drake, J. C., Chabner. B. A., Elwood, P. C., Zinn, S., and Allegra, C. J. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl. Acad. Sci. USA, 88: 8977-8981, 1991.
49. Pullarkat, S., Ghaderi, V., Ingles, S., Xiong, Y., Chen, P., Stoelmacher, J., Gupta, M., Tsao-Wei, D., Groshen, S., and Lenz, H-J. Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy. Proc. Am. Soc. Clin. Oncol., 19: 243a, 2000.
50. Keyomarsi, K., Samet, J., Molnar, G., and Pardee, A. B. The thymidylate synthase inhibitor. ICI D1694, overcomes translational detainment of the enzyme. J. Biol. Chem., 268: 15142-15149, 1993.
51. Gorlick, R., Metzger, R., Danenberg, K. D., Salonga, D., Miles, J. S., Longo, G. S., Fu, J., Banerjee, D., Klimstra, D., Jhanwar, S., Danenberg, P. V., Kemeny, N., and Bertino, J. R. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol., 16: 1465-1469, 1998.
52. Edler, D., Glimelius. B., Hallstrom, M., Jakobsen, A., Johnston, P. G., Magnusson, I., Ragnhammer, P., and Blomgren, H. Thymidylate synthase expression in colorectal cancer - a prognostic and predictive marker of benefit from adjuvant fluorouracil based chemotherapy, Proc. Am. Soc. Clin. Oncol., 20: 124a, 2001.
53. Kemeny, N., Niedzweicki, D., Shurgot, B., and Oderman, P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer (Phila.), 63: 742-747, 1989.
54. Chu, E., Takechi, T., Jones, K. L., Voeller, D. M., Copur, S. M., Maley, G. F., Maley, F., Segal, S., and Allegra, C. J. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol. Cell. Biochem., 15: 179-185, 1995.
55. Chu, E., Copur, S. M., Ju, J., Chen, T. M., Khleif, S., Voeller, D. M., Mizunuma, N., Patel, M., Maley, G. F., Maley, F., and Allegra, C. J. Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. Mol. Cell. Biol., 19: 1582-1594, 1999.
56. Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
57. Patterson, A., Talbot, D., Stratford, I., and Harris, A. L. Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro. Cancer Res., 58: 2737-2740, 1998.
58. Davies, M. M., Johnston, P. G., Kaur, S., and Allen-Mersh, T. G. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin. Cancer Res. 5: 325-328, 1999.